{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:12:05Z","timestamp":1771377125990,"version":"3.50.1"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Applied Radiation and Isotopes"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.apradiso.2026.112466","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:05:53Z","timestamp":1769155553000},"page":"112466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hypofractionated VMAT for prostate cancer: Integrating second-cancer modelling into clinical and policy decisions"],"prefix":"10.1016","volume":"230","author":[{"given":"Amit Kumar","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha","family":"Putcha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varshini","family":"Vadhithala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apradiso.2026.112466_bib1","article-title":"Toxicity and second primary cancer estimate for hypo-and-conventionally fractionated volumetric modulated arc-therapy of prostate carcinoma","volume":"229","author":"Boughalia","year":"2025","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.apradiso.2026.112466_bib3","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1002\/mp.14169","article-title":"Secondary bladder and rectal cancer risk estimates following standard fractionated and moderately hypofractionated VMAT for prostate carcinoma","volume":"47","author":"Mazonakis","year":"2020","journal-title":"Med. Phys."},{"key":"10.1016\/j.apradiso.2026.112466_bib2","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 Patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.apradiso.2026.112466_bib4","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"Br. Med. J."}],"container-title":["Applied Radiation and Isotopes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804326000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804326000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:33:12Z","timestamp":1771374792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969804326000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":4,"alternative-id":["S0969804326000503"],"URL":"https:\/\/doi.org\/10.1016\/j.apradiso.2026.112466","relation":{},"ISSN":["0969-8043"],"issn-type":[{"value":"0969-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated VMAT for prostate cancer: Integrating second-cancer modelling into clinical and policy decisions","name":"articletitle","label":"Article Title"},{"value":"Applied Radiation and Isotopes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apradiso.2026.112466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112466"}}